Brainstorm Cell Therapeutics's total assets for Q3 2024 were $2.02M, a decrease of -64.37% from the previous quarter. BCLI total liabilities were $8.08M for the fiscal quarter, a -12.25% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.